PMV Pharmaceuticals, Inc.
PMVP
$1.00
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 106.54% | -18.22% | -11.74% | -21.41% | -10.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.15% | 11.51% | 0.24% | -18.31% | -10.68% |
| Operating Income | -33.15% | -11.51% | -0.24% | 18.31% | 10.68% |
| Income Before Tax | -45.97% | -15.10% | 0.26% | 20.17% | 18.55% |
| Income Tax Expenses | 100.00% | -- | -404,425.00% | -- | -- |
| Earnings from Continuing Operations | -45.98% | -15.54% | 93.04% | 20.17% | 18.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.98% | -15.54% | 93.04% | 20.17% | 18.55% |
| EBIT | -33.15% | -11.51% | -0.24% | 18.31% | 10.68% |
| EBITDA | -35.52% | -11.66% | -0.23% | 19.36% | 12.06% |
| EPS Basic | -44.78% | -9.87% | 93.80% | 28.98% | 27.55% |
| Normalized Basic EPS | -44.78% | -9.48% | 11.23% | 32.12% | 27.56% |
| EPS Diluted | -44.78% | -9.87% | 93.80% | 28.98% | 27.55% |
| Normalized Diluted EPS | -44.78% | -9.48% | 11.23% | 32.12% | 27.56% |
| Average Basic Shares Outstanding | 0.83% | 5.15% | 12.37% | 12.39% | 12.43% |
| Average Diluted Shares Outstanding | 0.83% | 5.15% | 12.37% | 12.39% | 12.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |